ATRX and soft tissue sarcoma: Regardless of which additional mechanisms are involved, our finding that Atrx deletion increased soft tissue sarcoma susceptibility to dsDNA oncolytic herpesvirus in vitro suggests that patients with sarcomas and perhaps other tumors with ATRX loss-of-function mutations may benefit from oncolytic virus (OV) therapy.